BioPharma Resources

Drug Trial Radar · NCT07935317

A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer

A Phase 2, Open-label, Randomized Study Investigating the Tolerability of Concurrent Versus Staggered Administration of Abemaciclib and Endocrine Therapy With Tersolisib in Patients With HR+, HER2- Node-Positive, PIK3CA-Mutated Early Breast Cancer.

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare two ways of giving the anti-cancer medicines abemaciclib and hormone therapy with tersolisib in participants with early breast cancer that has a genetic mutation (PIK3CA mutation). For each participant, the study will last up to 56 weeks and include 12 visits.

Conditions

  • Breast Neoplasms

Interventions

  • AbemaciclibDrug

    Administered orally

  • TersolisibDrug

    Administered orally

  • LetrozoleDrug

    Administered orally

  • AnastrozoleDrug

    Administered orally

  • ExemestaneDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Participants who Discontinue Tersolisib Due to Treatment Emergent Adverse Events (TEAEs).Time frame: Cycle 1 through study completion (estimated as 56 weeks)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • USO - Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Stefanie Spielman Comprehensive Breast Center

    Columbus, Ohio

  • Texas Oncology - West Texas

    Amarillo, Texas

  • Texas Oncology - Balcones

    Austin, Texas

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas

  • USO - Virginia Cancer Specialists

    Reston, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.